Christian Glennie
Stock Analyst at Stifel Nicolaus
(2.96)
# 2,726
Out of 5,125 analysts
77
Total ratings
39.5%
Success rate
3.5%
Average return
Main Sectors:
Stocks Rated by Christian Glennie
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: CTEC Convatec Group PLC | Reiterated: Buy | 315p | 249p | +26.71% | 11 | Aug 4, 2026 | |
| AIM: AMS Advanced Medical Solutions Group plc | Reiterated: Buy | 245p | 283p | -13.43% | 12 | May 21, 2026 | |
| AIM: DXRX Diaceutics PLC | Reiterated: Buy | 225p | 193p | n/a | 10 | Sep 23, 2025 | |
| AIM: EKF EKF Diagnostics Holdings plc | Reiterated: Buy | 29p → 35p | 24p | n/a | 5 | Sep 16, 2025 | |
| LON: GNS Genus plc | Reiterated: Hold | 1,850p → 2,300p | 2,338p | n/a | 7 | Sep 9, 2025 | |
| LON: HIK Hikma Pharmaceuticals PLC | Reiterated: Buy | 2,650p | 1,625p | n/a | 8 | Apr 24, 2025 | |
| SUPN Supernus | Reiterated: Buy | $15 | $28.75 | n/a | 4 | Apr 24, 2025 | |
| AMS: PHARM Pharming Group N.V. | Reiterated: Buy | n/a | $1.17 | n/a | 4 | Jun 4, 2024 | |
| AIM: AVCT Avacta Group Plc | Reiterated: Buy | 105p | 54p | n/a | 3 | May 23, 2024 | |
| BME: PHM Pharma Mar, S.A. | Downgraded: Hold | €109.00 | €69.00 | n/a | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 4,441p → 4,071p | 1p | n/a | 3 | Jul 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 7,031p → 5,551p | 43p | n/a | 2 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 15,394p → 13,914p | 76p | n/a | 4 | Jun 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 12,952p | 0.10p | n/a | 3 | May 18, 2017 |
Convatec Group PLC
Aug 4, 2026
Reiterated: Buy
Price Target: 315p
Current: 249p
Upside: +26.71%
Advanced Medical Solutions Group plc
May 21, 2026
Reiterated: Buy
Price Target: 245p
Current: 283p
Upside: -13.43%
Diaceutics PLC
Sep 23, 2025
Reiterated: Buy
Price Target: 225p
Current: 193p
Upside: n/a
EKF Diagnostics Holdings plc
Sep 16, 2025
Reiterated: Buy
Price Target: 29p → 35p
Current: 24p
Upside: n/a
Genus plc
Sep 9, 2025
Reiterated: Hold
Price Target: 1,850p → 2,300p
Current: 2,338p
Upside: n/a
Hikma Pharmaceuticals PLC
Apr 24, 2025
Reiterated: Buy
Price Target: 2,650p
Current: 1,625p
Upside: n/a
Supernus
Apr 24, 2025
Reiterated: Buy
Price Target: $15
Current: $28.75
Upside: n/a
Pharming Group N.V.
Jun 4, 2024
Reiterated: Buy
Price Target: n/a
Current: $1.17
Upside: n/a
Avacta Group Plc
May 23, 2024
Reiterated: Buy
Price Target: 105p
Current: 54p
Upside: n/a
Pharma Mar, S.A.
Nov 11, 2020
Downgraded: Hold
Price Target: €109.00
Current: €69.00
Upside: n/a
Jul 25, 2018
Reiterated: Buy
Price Target: 4,441p → 4,071p
Current: 1p
Upside: n/a
May 24, 2018
Reiterated: Buy
Price Target: 7,031p → 5,551p
Current: 43p
Upside: n/a
Jun 8, 2017
Reiterated: Buy
Price Target: 15,394p → 13,914p
Current: 76p
Upside: n/a
May 18, 2017
Reiterated: Buy
Price Target: 12,952p
Current: 0.10p
Upside: n/a